Gamma-AApeptides Broad-Spectrum Antimicrobial Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides face challenges such as immunoreactivity, enzymatic susceptibility, and resistance development, as well as complexity in designing non-natural peptidomimetics with fine-tuned activity and selectivity, while conventional antibiotics struggle with broad-spectrum efficacy and resistance issues.
Innovation Solution
Development of γ-AApeptides, a novel class of antimicrobial agents including linear, cyclic, and lipidated γ-AApeptides with a simple design strategy, which are stable, non-toxic, and resistant to proteolytic hydrolysis, exhibiting broad-spectrum activity and low propensity for resistance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then specific metabolic processes in bacteria are targeted, but antibiotic resistance develops and broad-spectrum efficacy is limited
Solution Approach 1:
The patent changes the fundamental parameters of antimicrobial agents by transitioning from conventional antibiotics to antimicrobial peptides and their peptidomimetics (such as γ-AApeptides with γ-amino acid backbones). This parameter change enables broad-spectrum activity against Gram-positive and Gram-negative bacteria while maintaining reliability through peptide-based mechanisms that target cell membranes rather than specific metabolic processes
2Adaptability or versatility
If antimicrobial peptides are developed to provide broad-spectrum activity, then resistance mechanisms are avoided, but immunoreactivity and enzymatic degradation occur
Solution Approach 1:
The patent creates peptidomimetic copies of natural antimicrobial peptides that replicate their broad-spectrum antimicrobial activity while improving stability. Specifically, γ-AApeptides copy the functional properties of natural peptides but use non-natural γ-amino acid backbones that resist proteolytic degradation, thereby maintaining reliability while preserving adaptability
Solution Approach 2:
The patent develops composite peptidomimetic structures combining γ-amino acid backbones with side chains that mimic natural peptide functionality. This composite approach creates molecules that exhibit both broad-spectrum antimicrobial activity and enhanced stability against enzymatic degradation, resolving the contradiction between versatility and reliability
3Reliability
If non-natural peptidomimetics are designed to improve resistance to proteolytic hydrolysis, then stability is enhanced, but design complexity increases
Solution Approach 1:
The patent systematically changes the backbone parameter from α-amino acids to γ-amino acids, creating a new class of peptidomimetics with inherent resistance to proteolytic hydrolysis. This single parameter change provides stability while maintaining relatively simple design compared to other non-natural peptidomimetics, as the γ-amino acid framework preserves peptide-like functionality with improved stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
γ-AApeptides demonstrate potent antimicrobial activity against clinically relevant strains, including multi-drug resistant bacteria and fungi, with low hemolytic activity and no observed resistance development, offering a promising alternative to conventional antibiotics.
Implementation Method 1
antimicrobial peptides are able to form amphipathic structures, where cationic and hydrophobic groups are segregated into two regions, so as to facilitate interaction with the negatively charged bacterial cytoplasmic membrane
Implementation Method 2
facilitate interaction with the negatively charged bacterial cytoplasmic membrane
Data Source
AI summary
The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.